Reports of Symptoms Associated with Supraventricular Arrhythmias as a Serious Adverse Drug Reaction in the Spanish Pharmacovigilance Database

Pueyo-Val, Javier (Universidad de Zaragoza) ; Avedillo-Salas, Ana (Universidad de Zaragoza) ; Berdún-Viñegra, Pablo ; Pueyo-Val, Olga María ; Fanlo-Villacampa, Ana (Universidad de Zaragoza) ; Navarro-Pemán, Cristina (Universidad de Zaragoza) ; Lanuza-Giménez, Francisco Javier (Universidad de Zaragoza) ; Ioakeim-Skoufa, Ignatios ; Vicente-Romero, Jorge (Universidad de Zaragoza)

Resumen: This study aimed to determine the type of drugs reported as suspected of causing severe supraventricular arrhythmias from the Spanish Human Pharmacovigilance System database. A total of 1053 reports were analysed, of which 526 (50%) were on men and 516 (49%) were on women. The most affected age group was the over-65s, with 593 reports (56%). Of the 1613 drugs, those belonging to the cardiovascular system (ATC Group C) were the most numerous (414 reports, 26%), with digoxin being the most frequent drug (49 reports, 12%). Other common groups were antiinfectives for systemic use (ATC Group J; 306 reports, 19%), antineoplastic and immunomodulating agents (ATC Group L; 198 reports, 12%), and nervous system drugs (ATC Group N; 185 reports, 11%). The most common supraventricular arrhythmia was atrial fibrillation (561 reports, 51%). Regarding outcomes, 730 (66%) patients recovered, 76 (7%) did not recover, 25 (3%) recovered but with sequelae, and 23 (2%) resulted in death. This study revealed that certain drugs have reported to be associated more frequently to supraventricular arrhythmias as serious adverse reactions, especially in the older population. Proper clinical management and effective strategies to ensure medication appropriateness should always be considered to improve patient safety when prescribing drugs.

Idioma: Inglés

DOI: 10.3390/ph16081161

Año: 2023

Publicado en: Pharmaceuticals 16, 8 (2023), 1161 [12 pp.]
ISSN: 1424-8247

Factor impacto JCR: 4.3 (2023)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 69 / 354 = 0.195 (2023) - Q1 - T1
Categ. JCR: CHEMISTRY, MEDICINAL rank: 20 / 72 = 0.278 (2023) - Q2 - T1

Factor impacto SCIMAGO: 0.845 - Pharmaceutical Science (Q1) - Drug Discovery (Q2) - Molecular Medicine (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Farmacología (Dpto. Farmac.Fisiol.y Med.L.F.)